Why the study?
This review aimed to investigate the factors, mechanisms, laboratory evaluation methods, and clinical implications of clopidogrel resistance, its correlation with harmful cardiovascular events, and potential solutions including new-generation alternative antiplatelet agents.
Design
Review article
Authors
Loading...
May guide alternative P2Y12 use in resistant patients; leaves open need for randomized outcome trials before adoption.
Clopidogrel resistance, primarily driven by inadequate active metabolite generation due to genetic or metabolic factors, can be potentially managed by utilizing higher doses or alternative P2Y12 inhibitors.
Raghavendra et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: